A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) Study

• Jorge Aparicio,

  Affiliation Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

  ⨯
• Carmen García-Mora,

  Affiliation Department of Radiation Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain

  ⨯
• Marta Martín,

  Affiliation Department of Medical Oncology, Hospital de Sant Pau, Barcelona, Spain

  ⨯
• Ma Lourdes Petriz,

  Affiliation Department of Radiation Oncology, Hospital de Sant Pau, Barcelona, Spain

  ⨯
• Jaime Feliu,

  Affiliation Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain

  ⨯
• Ma Elena Sánchez-Santos,

  Affiliation Department of Radiation Oncology, Hospital Universitario La Paz, Madrid, Spain

  ⨯
• Juan Ramón Ayuso,

  Affiliation Department of Radiology, Hospital Clínic, Barcelona, Spain

  ⨯
• David Fuster,

  Affiliation Department of Nuclear Medicine, Hospital Clínic, Barcelona, Spain

  ⨯
• Carlos Conill,

  Affiliation Department of Radiation Oncology, Hospital Clínic, Barcelona, Spain

  ⨯
• Joan Maurel

  * E-mail: jmaurel@clinic.ub.es

  Affiliation Department of Medical Oncology, Hospital Clínic, Barcelona, Spain

  ⨯